HBV_Eligibility_Results.csv

Case ID,Age,Sex,Pregnancy Status,HBsAg,HBeAg,HBV DNA (IU/mL),ALT (U/L),Fibrosis/Cirrhosis Stage,Necroinflammation,Extrahepatic Manifestations,Immunosuppressive Therapy,Coinfections,Family History of HCC/Cirrhosis,Smoking,Comorbidities,Eligibility,Rationale
Case1,28,M,No,Positive (36 months),Positive,8500000,120,F1,Moderate,No,,,No,No,,True,"Eligibility and Rationale:
- Eligible: HBV DNA > 2,000 IU/mL and ALT > ULN, with moderate necroinflammation (Grade A) [SASLT 2021, Page 6]
- Meets criteria for treatment due to HBV DNA > 20,000 IU/mL and ALT > 2xULN (Grade B) [SASLT 2021, Page 6]

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]

Monitoring and Follow-up:
- Monitor treatment response per SASLT protocol every 3-6 months (Grade B) [SASLT 2021, Page 7]

Special Considerations:
- None applicable as patient has no coinfections, immunosuppression, or extrahepatic manifestations [SASLT 2021, Pages 6-9]

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
Case2,45,F,No,Positive (60 months),Negative,15000,65,F1–F2,Moderate,No,,,No,No,Metabolic syndrome,True,"Eligibility and Rationale:
- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, moderate fibrosis (Grade A) [SASLT 2021, Page 6]
- Necroinflammatory activity (A2) supports treatment initiation (Grade A) [SASLT 2021, Page 6]

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]

Monitoring and Follow-up:
- Monitor treatment response per SASLT protocol every 3-6 months (Grade D) [SASLT 2021, Page 7]

Special Considerations:
- Metabolic syndrome may require additional management alongside HBV treatment [SASLT 2021, Page 6]

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
Case3,52,M,No,Positive (120 months),Negative,3500,32,F2–F3,Mild,No,,,No,No,,True,"Eligibility and Rationale:
- Eligible: HBV DNA > 2,000 IU/mL, moderate fibrosis (F2-F3), and chronic HBV infection (Grade A) [SASLT 2021, Page 6].
- ALT is within normal limits but fibrosis stage supports treatment initiation (Grade A) [SASLT 2021, Page 6].

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF as first-line treatment (Grade A) [SASLT 2021, Page 8].

Monitoring and Follow-up:
- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months (Grade A) [SASLT 2021, Page 7].

Special Considerations:
- None applicable as patient has no coinfections, immunosuppression, or extrahepatic manifestations [SASLT 2021, Pages 6, 9].

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
Case4,60,M,No,Positive (240 months),Negative,700,28,F4 (compensated),Mild,No,,,No,No,,True,"Eligibility and Rationale:
- Eligible: Cirrhosis (F4) with detectable HBV DNA, regardless of ALT levels (Grade A) [SASLT 2021, Page 6]

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]

Monitoring and Follow-up:
- Monitor treatment response per SASLT protocol every 3-6 months (Grade A) [SASLT 2021, Page 7]

Special Considerations:
- None applicable to this patient [SASLT 2021, Pages 6-10]

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
Case5,22,F,No,Positive (18 months),Positive,25000000,27,F0,,No,,,No,No,,False,"Eligibility and Rationale:
- Not eligible: HBV DNA > 20,000 IU/mL but ALT ≤ 2xULN and age < 30 years (Grade B) [SASLT 2021, Page 6].
- No significant fibrosis or necroinflammation (F0-F1, A0) and no family history of HCC or cirrhosis [SASLT 2021, Page 6].

Treatment Recommendations:
- Treatment not indicated at this time [SASLT 2021, Page 6].

Monitoring and Follow-up:
- Monitor every 3-6 months for HBeAg-positive patients under 30 years (Grade B) [SASLT 2021, Page 7].

Special Considerations:
- None applicable to this patient.

References:
- Pages 6, 7: Treatment criteria, monitoring protocols"
Case6,40,M,No,Positive (84 months),Negative,900,22,F0–F1,,No,,,No,No,,False,"Eligibility and Rationale:
- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, no significant fibrosis or necroinflammation [SASLT 2021, Page 6].

Treatment Recommendations:
- Treatment not indicated at this time [SASLT 2021, Page 6].

Monitoring and Follow-up:
- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7].

References:
- Pages 6, 7: Treatment criteria, monitoring protocols"
Case7,31,F,Yes (28 weeks),Positive (48 months),Positive,500000,35,F1,Mild,No,,,No,No,,True,"Eligibility and Rationale:
- Eligible: HBV DNA > 100,000 IU/mL during pregnancy warrants antiviral prophylaxis starting at 24-28 weeks (Grade D) [SASLT 2021, Page 10].
- Eligible: HBeAg-positive chronic HBV infection with high HBV DNA levels (> 20,000 IU/mL) and age > 30 years (Grade D) [SASLT 2021, Page 6].

Treatment Recommendations:
- Start antiviral prophylaxis with TDF or TAF at 24-28 weeks of pregnancy (Grade D) [SASLT 2021, Page 10].
- Preferred regimens for CHB treatment include TDF, TAF, or ETV monotherapy (Grade A) [SASLT 2021, Page 8].

Monitoring and Follow-up:
- Monitor HBV DNA and ALT levels every 3 months during pregnancy and postpartum (Grade D) [SASLT 2021, Page 7].
- Assess treatment response and adjust therapy as needed per SASLT protocol [SASLT 2021, Page 7].

Special Considerations:
- Breastfeeding is permitted for HBsAg-positive women on TDF (Grade B) [SASLT 2021, Page 10].

References:
- Pages 6, 7, 8, 10: Treatment criteria, drugs, monitoring, pregnancy-related recommendations"
Case8,35,M,No,Positive (72 months),Positive,9000000,33,F1,Mild,No,,,No,No,,True,"Eligibility and Rationale:
- Eligible: HBeAg-positive chronic HBV infection, age > 30 years, persistently high HBV DNA levels (Grade D) [SASLT 2021, Page 6].
- HBV DNA > 2,000 IU/mL and ALT ≤ ULN, meeting treatment criteria for HBeAg-positive patients > 30 years (Grade D) [SASLT 2021, Page 6].

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8].

Monitoring and Follow-up:
- Monitor treatment response per SASLT protocol every 3-6 months (Grade B) [SASLT 2021, Page 7].

Special Considerations:
- None applicable to this patient.

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
Case9,55,F,No,Positive (180 months),Negative,6200,45,F1–F2,Moderate,No,,,Yes (father HCC),No,,True,"Eligibility and Rationale:
- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, moderate fibrosis (Grade A) [SASLT 2021, Page 6]
- Family history of HCC or cirrhosis supports treatment initiation (Grade D) [SASLT 2021, Page 6]

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]

Monitoring and Follow-up:
- Monitor treatment response per SASLT protocol every 3-6 months [SASLT 2021, Page 7]

Special Considerations:
- None applicable to this patient [SASLT 2021, Pages 6-10]

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
Case10,63,M,No,Positive (300 months),Negative,50,32,F4 (decompensated),Mild,No,,,No,No,,True,"Eligibility and Rationale:
- Eligible: Patient has cirrhosis (F4 fibrosis) with detectable HBV DNA, regardless of ALT levels (Grade A) [SASLT 2021, Page 6].

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF as first-line treatment (Grade A) [SASLT 2021, Page 8].

Monitoring and Follow-up:
- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months [SASLT 2021, Page 7].

Special Considerations:
- None applicable as patient has no coinfections, immunosuppression, or extrahepatic manifestations [SASLT 2021, Pages 6, 9].

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
Case11,68,M,No,Positive (25 years),Negative,5800,41,F2,Mild,No,,,No,No,Diabetes,True,"Eligibility and Rationale:
- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, and moderate fibrosis (F2-F3) (Grade A) [SASLT 2021, Page 6]
- Chronic HBV infection with significant liver disease warrants treatment initiation (Grade A) [SASLT 2021, Page 6]

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF as first-line treatment (Grade A) [SASLT 2021, Page 8]

Monitoring and Follow-up:
- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months (Grade A) [SASLT 2021, Page 7]

Special Considerations:
- Patient's age (68 years) and comorbidity (diabetes) may require closer monitoring for treatment-related side effects [SASLT 2021, Page 6]

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
Case12,50,F,No,Positive,Negative,450,32,,Mild,No,Yes (tacrolimus),,No,No,Post-transplant,False,"Eligibility and Rationale:
- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, no significant fibrosis or necroinflammation [SASLT 2021, Page 6].

Treatment Recommendations:
- Treatment not indicated at this time [SASLT 2021, Page 6].

Monitoring and Follow-up:
- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7].

Special Considerations:
- Immunosuppression: Consider prophylaxis if undergoing immunosuppressive therapy (Grade A) [SASLT 2021, Page 9].

References:
- Pages 6, 7, 9: Treatment criteria, monitoring protocols, immunosuppression considerations"
Case13,27,M,No,Positive (36 months),Negative,1700,55,F1,Mild,No,,,No,No,,False,"Eligibility and Rationale:
- Not eligible: HBV DNA < 2,000 IU/mL, ALT > ULN but mild fibrosis and necroinflammation (Grade A) [SASLT 2021, Page 6]

Treatment Recommendations:
- Treatment not indicated at this time [SASLT 2021, Page 6]

Monitoring and Follow-up:
- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7]

Special Considerations:
- None applicable to this patient [SASLT 2021, Pages 6-10]

References:
- Pages 6, 7: Treatment criteria, monitoring protocols"
Case14,44,F,No,Positive,Negative,3000,70,F2,Moderate,No,,HCV RNA positive,No,No,,True,"Eligibility and Rationale:
- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, and moderate fibrosis (Grade A) [SASLT 2021, Page 6].
- HBV-HCV coinfection requires concurrent or prior HBV treatment to prevent reactivation during DAA therapy (Grade A) [SASLT 2021, Page 9].

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8].

Monitoring and Follow-up:
- Monitor HBV DNA and ALT every 4-8 weeks during DAA therapy and three months post-therapy (Grade D) [SASLT 2021, Page 9].
- Monitor treatment response per SASLT protocol (Grade A) [SASLT 2021, Page 7].

Special Considerations:
- HBV-HCV coinfection requires close monitoring to prevent HBV reactivation during HCV treatment (Grade A) [SASLT 2021, Page 9].

References:
- Pages 6, 7, 8, 9: Treatment criteria, drugs, monitoring, HBV-HCV coinfection"
Case15,33,M,No,Positive,Negative,25000,30,F1,Mild,No,,HIV positive,No,No,,False,"Eligibility and Rationale:
- Not eligible: HBV DNA > 2,000 IU/mL but ALT ≤ ULN and no significant fibrosis or necroinflammation (Grade A) [SASLT 2021, Page 6].

Treatment Recommendations:
- Treatment not indicated at this time [SASLT 2021, Page 6].

Monitoring and Follow-up:
- Monitor every 3 months for the first year, then every 6 months (HBeAg-negative, HBV DNA ≥ 2,000 IU/mL) (Grade D) [SASLT 2021, Page 7].

Special Considerations:
- HBV-HIV coinfection: ensure ART includes TDF- or TAF-based regimen (Grade A) [SASLT 2021, Page 9].

References:
- Pages 6, 7, 9: Treatment criteria, monitoring protocols, HIV coinfection"
Case16,30,F,Yes (30 weeks),Positive,Positive,40000,28,F0,,No,,,No,No,,False,"Eligibility and Rationale:
- Not eligible: HBV DNA > 2,000 IU/mL but ALT ≤ ULN and no significant fibrosis or necroinflammation [SASLT 2021, Page 6].
- Pregnancy alone does not meet treatment criteria unless HBV DNA > 100,000 IU/mL at 24-28 weeks [SASLT 2021, Page 10].

Treatment Recommendations:
- Treatment not indicated at this time [SASLT 2021, Page 6].

Monitoring and Follow-up:
- Monitor every 3-6 months for HBeAg-positive patients under 30 years (Grade B) [SASLT 2021, Page 7].
- Assess HBV DNA and ALT levels regularly to evaluate disease progression [SASLT 2021, Page 6].

Special Considerations:
- Consider antiviral prophylaxis with TDF if HBV DNA exceeds 100,000 IU/mL at 24-28 weeks of pregnancy [SASLT 2021, Page 10].

References:
- Pages 6, 7, 10: Treatment criteria, monitoring protocols, pregnancy considerations"
Case17,39,M,No,Positive,Negative,4800,250,F1,Marked,No,,,No,No,,True,"Eligibility and Rationale:
- Eligible: HBV DNA > 2,000 IU/mL and ALT > ULN, regardless of HBeAg status (Grade A) [SASLT 2021, Page 6]
- ALT > 2x ULN supports treatment initiation (Grade B) [SASLT 2021, Page 6]

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]

Monitoring and Follow-up:
- Monitor treatment response per SASLT protocol every 3-6 months (Grade B) [SASLT 2021, Page 7]

Special Considerations:
- None applicable to this patient [SASLT 2021, Pages 6-10]

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
Case18,49,F,No,Positive,Negative,2300,37,F1,Mild,No,,,Yes (mother cirrhosis),No,,True,"Eligibility and Rationale:
- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, and family history of HCC or cirrhosis (Grade D) [SASLT 2021, Page 6].

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8].

Monitoring and Follow-up:
- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months [SASLT 2021, Page 7].

Special Considerations:
- Family history of HCC or cirrhosis increases the need for treatment to reduce long-term risks [SASLT 2021, Page 6].

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
Case19,56,M,No,Positive,Negative,10,30,F4 (compensated),Mild,No,,,No,No,,True,"Eligibility and Rationale:
- Eligible: Patient has cirrhosis (F4 fibrosis) with detectable HBV DNA, regardless of ALT levels (Grade A) [SASLT 2021, Page 6].

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF as first-line treatment (Grade A) [SASLT 2021, Page 8].

Monitoring and Follow-up:
- Monitor treatment response per SASLT protocol every 3-6 months (Grade A) [SASLT 2021, Page 7].

Special Considerations:
- None applicable to this patient.

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
Case20,41,F,No,Positive (10 years),Negative,1900,28,F1,Mild,No,,,No,No,,False,"Eligibility and Rationale:
- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, no significant fibrosis or necroinflammation (Grade A) [SASLT 2021, Page 6]

Treatment Recommendations:
- Treatment not indicated at this time [SASLT 2021, Page 6]

Monitoring and Follow-up:
- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7]

Special Considerations:
- None applicable to this patient [SASLT 2021, Page 6]

References:
- Pages 6, 7: Treatment criteria, monitoring protocols"
Case21,56,F,No,Positive,Negative,0,20,F4 (compensated),Mild,No,,,No,No,,True,"Eligibility and Rationale:
- Eligible: Patient has cirrhosis (F4 fibrosis) with detectable HBsAg, regardless of HBV DNA and ALT levels (Grade A) [SASLT 2021, Page 6].

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF as the preferred treatment options (Grade A) [SASLT 2021, Page 8].

Monitoring and Follow-up:
- Monitor treatment response per SASLT protocol, including HBV DNA, ALT, and fibrosis assessment [SASLT 2021, Page 7].

Special Considerations:
- None applicable as the patient has no coinfections, immunosuppression, or other special conditions [SASLT 2021, Pages 6-10].

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
Case22,70,M,No,Positive (30 years),Negative,1800,27,F2,Mild,No,,,No,Yes (smoker),Hypertension,False,"Eligibility and Rationale:
- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, moderate fibrosis but does not meet treatment thresholds [SASLT 2021, Page 6].

Treatment Recommendations:
- Treatment not indicated at this time [SASLT 2021, Page 6].

Monitoring and Follow-up:
- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7].

References:
- Pages 6, 7: Treatment criteria, monitoring protocols"
Case23,33,F,Yes (12 weeks),Positive,Positive,300000,40,F1,Mild,No,,,No,No,,True,"Eligibility and Rationale:
- Eligible: HBV DNA > 100,000 IU/mL during pregnancy warrants antiviral prophylaxis (Grade D) [SASLT 2021, Page 10]
- ALT > ULN and HBeAg-positive status further support treatment initiation (Grade A) [SASLT 2021, Page 6]

Treatment Recommendations:
- Start antiviral prophylaxis with TDF or TAF at 24-28 weeks of pregnancy (Grade D) [SASLT 2021, Page 10]
- Preferred regimens include TDF or TAF as monotherapy (Grade A) [SASLT 2021, Page 8]

Monitoring and Follow-up:
- Monitor HBV DNA and ALT levels every 3 months during treatment (Grade D) [SASLT 2021, Page 7]
- Postpartum follow-up to assess treatment continuation or cessation [SASLT 2021, Page 10]

Special Considerations:
- Breastfeeding is permitted while on TDF therapy (Grade B) [SASLT 2021, Page 10]

References:
- Pages 6, 7, 8, 10: Treatment criteria, drugs, monitoring, pregnancy considerations"
Case24,46,M,No,Positive (8 years),Negative,50000,48,F2,Moderate,Yes (vasculitis),,,No,No,,True,"Eligibility and Rationale:
- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, moderate fibrosis (Grade A) [SASLT 2021, Page 6]
- Extrahepatic manifestations further support treatment initiation (Grade D) [SASLT 2021, Page 6]

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]

Monitoring and Follow-up:
- Monitor treatment response every 3-6 months per SASLT protocol (Grade B) [SASLT 2021, Page 7]

Special Considerations:
- None applicable to this patient.

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
Case25,58,F,No,Positive,Negative,2000,60,F2,Moderate,No,,,No,No,CKD stage 3,True,"Eligibility and Rationale:
- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, moderate fibrosis (Grade A) [SASLT 2021, Page 6]
- Moderate necroinflammation (A2) and fibrosis (F2-F3) support treatment initiation (Grade A) [SASLT 2021, Page 6]

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]

Monitoring and Follow-up:
- Monitor treatment response every 3-6 months per SASLT protocol [SASLT 2021, Page 7]
- Assess HBV DNA, ALT, and fibrosis progression during follow-up [SASLT 2021, Page 7]

Special Considerations:
- CKD stage 3: Prefer TAF over TDF due to better renal safety profile (Grade A) [SASLT 2021, Page 8]

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
Case26,29,M,No,Positive,Positive,2500000,33,F0,,No,,,No,No,,False,"Eligibility and Rationale:
- Not eligible: HBV DNA > 2,000 IU/mL but ALT ≤ ULN and no significant fibrosis or necroinflammation [SASLT 2021, Page 6].

Treatment Recommendations:
- Treatment not indicated at this time [SASLT 2021, Page 6].

Monitoring and Follow-up:
- Monitor every 3-6 months (HBeAg-positive, HBV DNA > 2,000 IU/mL, ALT ≤ ULN) (Grade B) [SASLT 2021, Page 7].

Special Considerations:
- None applicable to this patient.

References:
- Pages 6, 7: Treatment criteria, monitoring protocols"
Case27,54,M,No,Positive,Negative,750,18,F4 (compensated),Mild,No,,,No,No,,True,"Eligibility and Rationale:
- Eligible: Patient has cirrhosis (F4 fibrosis) with detectable HBV DNA, regardless of ALT levels (Grade A) [SASLT 2021, Page 6].

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF as the preferred treatment options (Grade A) [SASLT 2021, Page 8].

Monitoring and Follow-up:
- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months [SASLT 2021, Page 7].

Special Considerations:
- None applicable as the patient has no coinfections, immunosuppression, or other special conditions [SASLT 2021, Pages 6-10].

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
Case28,38,F,No,Positive,Negative,6000,80,F2,Moderate,No,,,No,No,Obesity,True,"Eligibility and Rationale:
- Eligible: HBV DNA > 2,000 IU/mL, ALT > ULN, and moderate fibrosis (Grade A) [SASLT 2021, Page 6]
- Necroinflammatory activity (A2) and fibrosis stage (F2-F3) further support treatment initiation (Grade A) [SASLT 2021, Page 6]

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF as first-line treatment (Grade A) [SASLT 2021, Page 8]

Monitoring and Follow-up:
- Monitor treatment response per SASLT protocol, including HBV DNA and ALT levels every 3-6 months initially (Grade A) [SASLT 2021, Page 7]
- Assess fibrosis progression and treatment adherence regularly (Grade A) [SASLT 2021, Page 7]

Special Considerations:
- Obesity may impact liver disease progression; consider lifestyle interventions alongside antiviral therapy [SASLT 2021, Page 6]

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"
Case29,42,M,No,Positive,Negative,1200,25,F1,Mild,No,,,No,No,,False,"Eligibility and Rationale:
- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, no significant fibrosis or necroinflammation (Grade A) [SASLT 2021, Page 6].

Treatment Recommendations:
- Treatment not indicated at this time [SASLT 2021, Page 6].

Monitoring and Follow-up:
- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7].

References:
- Pages 6, 7: Treatment criteria, monitoring protocols"
Case30,25,F,No,Positive (2 years),Positive,12000000,95,F1,Moderate,No,,,No,No,,True,"Eligibility and Rationale:
- Eligible: HBV DNA > 20,000 IU/mL and ALT > 2xULN, regardless of fibrosis stage (Grade B) [SASLT 2021, Page 6]
- Moderate necroinflammatory activity (A2) supports treatment initiation (Grade A) [SASLT 2021, Page 6]

Treatment Recommendations:
- Start monotherapy with ETV, TDF, or TAF (Grade A) [SASLT 2021, Page 8]

Monitoring and Follow-up:
- Monitor treatment response per SASLT protocol every 3-6 months (Grade B) [SASLT 2021, Page 7]

Special Considerations:
- None applicable to this patient [SASLT 2021, Pages 6-10]

References:
- Pages 6, 7, 8: Treatment criteria, drugs, monitoring protocols"